Kristie L. Kahl

The risk for disease progression or death was reduced by 51% with subcutaneous Darzalex Faspro in certain patients with smoldering multiple myeloma.

Calquence plus Venclexta, with or without Gazyva, improved progression-free survival over the standard-of-care chemoimmunotherapy in patients with untreated chronic lymphocytic leukemia.

Long-term follow-data shows Revuforj to be effective in the treatment patients with R/R KMT2Ar acute leukemias.

For patients with transplant-ineligible or -deferred newly diagnosed multiple myeloma, the addition of Darzalex to VRd improved MRD responses as well as progression-free survival.

Following a CURE® Educated Patient® Lung Cancer Summit, the City of Hope expert answered 10 commonly asked questions from patients with lung cancer.

When compared with Zytiga, Xtandi appeared to have a lower incidence of infection among men with prostate cancer, especially those under 70 years.

Among patients with EGFR-mutated, advanced NSCLC, frontline treatment with Rybrevant plus Leclaza significantly prolonged progression-free survival.

Dato-DXd was efficacious in patients with non-small cell lung cancer with brain metastases who have certain gene alterations, a phase 2 study showed.

Patients with high-risk prostate cancer who had a higher dose of radiation plus long-term androgen deprivation therapy tended to live longer than those who had a lower dose.

Keytrida plus Lenvima improved survival and duration of response in patients with advanced hepatocellular carcinoma.

A nurse practitioner talks about personalized therapy and the role that genomic testing plays for patients with breast cancer.

Study findings support the use of a financial navigation program, in hopes of aiding patients with multiple myeloma affected by financial toxicity.

Brukinsa led to improved progression-free survival over Imbruvica in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, follow-up from the phase 3 ALPINE study showed.

Research demonstrated comparable outcomes in the real-world setting and in the phase 2 MajesTEC-1 trial when it came to treatment with Tecvayli for relapsed or refractory myeloma.

A phase 3 trial demonstrated progression-free survival improvements with Tecentriq-chemotherapy combination in patients with endometrial carcinoma.

Researchers continue to investigate novel immunotherapy drugs for the treatment of renal cell carcinoma.

In this on-demand webinar series, CURE partnered with Look Good Feel Better to offer fun wig options for patients to wear after hair loss from cancer treatment.

In this on-demand webinar series, CURE partnered with Look Good Feel Better to discuss how patients with cancer can care for their wig.

In this on-demand webinar series, CURE partnered with Look Good Feel Better to show how patients who experienced hair loss from cancer treatment can style their wigs.

In this on-demand webinar series, CURE partnered with Look Good Feel Better to demonstrate how to put on and adjust a wig for comfort and appearance for patients with cancer who have experienced hair loss from treatment.

In this on-demand webinar series, CURE partnered with Look Good Feel Better to offer patients with cancer offered tips for haircare and hair loss before, during and after treatment.

In this on-demand webinar series, CURE partnered with Look Good Feel Better to demonstrate makeup techniques in applying foundation and blush to combat appearance-related side effect from cancer treatment.

Patients with HR-positive, HER2-negative high-risk early breast cancer tended to experience improved invasive disease and distant relapse-free survival after adding Verzenio to endocrine therapy.

In this on-demand webinar series, CURE partnered with Look Good Feel Better to discuss skincare during cancer treatment to assist patients in their daily routine.

In this on-demand webinar series, CURE partnered with Look Good Feel Better to discuss eyebrow shaping techniques and applying eye shadow and mascara to address appearance-related effect from cancer treatment.

In this on-demand webinar series, CURE partnered with Look Good Feel Better to discuss lip care as part of one’s makeup routine to address appearance-related effects from cancer.

Dato-DXd lengthened the average time it took patients with HR-positive, HER2-low or -negative metastatic breast cancer to experience disease progression, study results showed.

The addition of Keytruda to Xtandi showed no improvements for radiographic progression-free survival and overall survival in patients with metastatic castration-resistant prostate cancer.

Adding Opdivo to a standard-of-care chemotherapy regimen in patients with unresectable or metastatic urothelial carcinoma improved progression-free and overall survival.

Treatment with neoadjuvant Opdivo, followed by Opdivo after surgery led to significantly improved event-free survival in the first phase 3 perioperative study in patients with resectable non-small cell lung cancer.